A Real-world Study of Tenecteplase Versus Alteplase for Thrombolysis in Patients Within 4.5 H of Onset of Ischemic Stroke

Launched by TIANJIN HUANHU HOSPITAL · Sep 28, 2024

Keywords

ClinConnect Summary

This clinical trial is studying two medications, tenecteplase and alteplase, which are used to treat acute ischemic strokes. An acute ischemic stroke happens when blood flow to the brain is blocked, which can lead to serious health issues. The goal of the study is to compare how safe and effective these two treatments are in real-world situations, helping doctors decide which one might be best for different patients.

To participate in this study, you need to be at least 18 years old and have had symptoms of a stroke for no more than 4.5 hours before starting treatment. You also need to give your consent or have a representative do so. However, certain people cannot join, such as those with severe allergies to either medication or those who have participated in another study recently. If you join, you'll be monitored closely to see how well the treatment works and if there are any side effects. This research aims to improve stroke treatment and ensure patients receive the best care possible.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - 1. Symptoms of neurological deficit caused by ischemic stroke; 2. The time from onset to treatment ≤4.5 hours; The time of onset of symptoms was defined as the time of last seen normal.
• • 3. Age ≥18 years old; 4. Signed informed consent by patients or their legally authorized representative.
• Exclusion Criteria:
• • 1. Any absolute contraindication to thrombolysis in the \"Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023\" 2.Allergy to TNK or alteplase 3.Participation in another clinical trial within the previous 3 months. 4.Other conditions deemed inappropriate for participation in this study.